Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review

References

• Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res. 2014;6:149–170. doi:10.2147/CMAR.S54726
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol. 1999;17(8):2572–2578. doi:10.1200/JCO.1999.17.8.2572
   PubMed Web of Science ®Google Scholar
• Aoki T, Hashimoto N, Matsutani M. Management of glioblastoma. Expert Opin Pharmacother. 2007;8(18):3133–3146. doi:10.1517/14656566.8.18.3133
   PubMed Web of Science ®Google Scholar
• Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw. 2005;3(5):721–728. doi:10.6004/jnccn.2005.0042
   PubMedGoogle Scholar
• Hsu BH, Lee WH, Yang ST, Han CT, Tseng YY. Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report. BMC Neurol. 2020;20(1):178. doi:10.1186/s12883-020-01768-3
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11(2):165–180. doi:10.1634/theoncologist.11-2-165
   PubMed Web of Science ®Google Scholar
• Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008;8(4):515–517. doi:10.1586/14737175.8.4.515
   PubMedGoogle Scholar
• Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep. 2011;11(3):305–312. doi:10.1007/s11910-011-0184-0
   PubMed Web of Science ®Google Scholar
• Lopez KA, Tannenbaum AM, Assanah MC, et al. Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res. 2011;71(11):3963–3971. doi:10.1158/0008-5472.CAN-10-0906
   PubMed Web of Science ®Google Scholar
• Tosi G, Ruozi B, Belletti D. Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine (Lond). 2012;7(8):1113–1116. doi:10.2217/nnm.12.90
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733–1744. doi:10.1007/s11095-007-9324-2
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008;5(2):155–174. doi:10.1517/17425247.5.2.155
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90–105, 151. doi:10.1124/mi.3.2.90
   PubMedGoogle Scholar
• Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193–209. doi:10.1016/j.jconrel.2007.09.013
   PubMed Web of Science ®Google Scholar
• Barbu E, Molnar E, Tsibouklis J, Gorecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv. 2009;6(6):553–565. doi:10.1517/17425240902939143
   PubMed Web of Science ®Google Scholar
• Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2(1):108–119. doi:10.1602/neurorx.2.1.108
   PubMedGoogle Scholar
• Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23(28):7178–7187. doi:10.1200/JCO.2005.06.502
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 2010;10(10):1537–1544. doi:10.1586/ern.10.32
   PubMed Web of Science ®Google Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403–419. doi:10.2165/00003088-200241060-00002
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 1993;53(2):329–333.
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, et al. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887–2893. doi:10.1245/s10434-008-0048-2
   PubMed Web of Science ®Google Scholar
• Dietrich J. Chemotherapy associated central nervous system damage. Adv Exp Med Biol. 2010;678:77–85.
   PubMedGoogle Scholar
• Westphal M, Hilt DC, Bortey E, et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88. doi:10.1093/neuonc/5.2.79
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 1995;345(8956):1008–1012. doi:10.1016/S0140-6736(95)90755-6
   PubMed Web of Science ®Google Scholar
• Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011;(3):CD007294. doi:10.1002/14651858.CD007294.pub2
   PubMedGoogle Scholar
• Tseng YY, Kau YC, Liu SJ. Advanced interstitial chemotherapy for treating malignant glioma. Expert Opin Drug Deliv. 2016;13(11):1533–1544. doi:10.1080/17425247.2016.1193153
   PubMed Web of Science ®Google Scholar
• Yen SY, Chen SR, Hsieh J, et al. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. Oncogene. 2016;35(17):2156–2165. doi:10.1038/onc.2015.277
   PubMed Web of Science ®Google Scholar
• Spicer CD, Pashuck ET, Stevens MM. Achieving controlled biomolecule-biomaterial conjugation. Chem Rev. 2018;118(16):7702–7743. doi:10.1021/acs.chemrev.8b00253
   PubMedGoogle Scholar
• Tseng YY, Liu SJ. Nanofibers used for the delivery of analgesics. Nanomedicine (Lond). 2015;10(11):1785–1800. doi:10.2217/nnm.15.23
   PubMed Web of Science ®Google Scholar
• Tseng YY, Liao JY, Chen WA, Kao YC, Liu SJ. Biodegradable poly([D,L]-lactide-co-glycolide) nanofibers for the sustainable delivery of lidocaine into the epidural space after laminectomy. Nanomedicine (Lond). 2014;9(1):77–87. doi:10.2217/nnm.13.42
   PubMed Web of Science ®Google Scholar
• Schiapparelli P, Zhang P, Lara-Velazquez M, et al. Self-assembling and self-formulating prodrug hydrogelator extends survival in a glioblastoma resection and recurrence model. J Control Release. 2020;319:311–321. doi:10.1016/j.jconrel.2020.01.003
   PubMed Web of Science ®Google Scholar
• Tseng YY, Yang TC, Chen SM, Yang ST, Tang YL, Liu SJ. Injectable SN-38-embedded polymeric microparticles promote antitumor efficacy against malignant glioma in an animal model. Pharmaceutics. 2020;12(5):479. doi:10.3390/pharmaceutics12050479
   PubMedGoogle Scholar
• Tseng YY, Kao CW, Liu KS, Tang YL, Liu YW, Liu SJ. Treating intracranial abscesses in rats with stereotactic injection of biodegradable vancomycin-embedded microparticles. Pharmaceutics. 2020;12(2):91. doi:10.3390/pharmaceutics12020091
   PubMedGoogle Scholar
• Liu SJ, Yang ST, Chen SM, et al. Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas. Ther Adv Med Oncol. 2019;11:1758835919875555. doi:10.1177/1758835919875555
   Google Scholar
• Liu SJ, Yang TC, Yang ST, Chen YC, Tseng YY. Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats. Artif Cells Nanomed Biotechnol. 2018;46(sup2):515–526. doi:10.1080/21691401.2018.1460374
   PubMed Web of Science ®Google Scholar
• Blumenthal DT, Rankin C, Stelzer KJ, et al. A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol. 2015;20(4):650–658. doi:10.1007/s10147-014-0769-0
   PubMedGoogle Scholar
• Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27(8):1262–1267. doi:10.1200/JCO.2008.18.8417
   PubMed Web of Science ®Google Scholar
• Tseng YY, Liao JY, Chen WA, Kao YC, Liu SJ. Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies. Expert Opin Drug Deliv. 2013;10(7):879–888. doi:10.1517/17425247.2013.758102
   PubMed Web of Science ®Google Scholar
• Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980;64(2–3):237–244.
   PubMedGoogle Scholar
• Kappelle AC, Postma TJ, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56(1):118–120. doi:10.1212/WNL.56.1.118
   PubMedGoogle Scholar
• Tseng YY, Wang YC, Su CH, et al. Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2015;134:254–261. doi:10.1016/j.colsurfb.2015.06.055
   PubMed Web of Science ®Google Scholar
• Tseng YY, Huang YC, Yang TC, et al. Concurrent chemotherapy of malignant glioma in rats by using multidrug-loaded biodegradable nanofibrous membranes. Sci Rep. 2016;6(1):30630. doi:10.1038/srep30630
   PubMedGoogle Scholar
• Smith SJ, Tyler BM, Gould T, et al. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res. 2019;25(16):5094–5106. doi:10.1158/1078-0432.CCR-18-3850
   PubMed Web of Science ®Google Scholar
• Yang J, Shi Z, Liu R, Wu Y, Zhang X. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics. 2020;10(7):3223–3239. doi:10.7150/thno.40298
   PubMed Web of Science ®Google Scholar
• Tseng YY, Su CH, Yang ST, et al. Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. Oncotarget. 2016;7(37):59902–59916. doi:10.18632/oncotarget.10989
   PubMedGoogle Scholar
• Galstyan A, Markman JL, Shatalova ES, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850. doi:10.1038/s41467-019-11719-3
   PubMedGoogle Scholar
• Kozielski KL, Ruiz-Valls A, Tzeng SY, et al. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. Biomaterials. 2019;209:79–87. doi:10.1016/j.biomaterials.2019.04.020
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanobiotechnology in the personalized management of glioblastoma multiforme. Nanomedicine (Lond). 2011;6(3):411–414. doi:10.2217/nnm.11.12
   PubMedGoogle Scholar
• Sneed PK, Gutin PH, Larson DA, et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys. 1994;29(4):719–727. doi:10.1016/0360-3016(94)90559-2
   PubMedGoogle Scholar
• Halperin EC, Burger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys. 1988;15(2):505–509. doi:10.1016/S0360-3016(98)90036-0
   PubMedGoogle Scholar
• Raza SM, Pradilla G, Legnani FG, et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther. 2005;5(4):477–494. doi:10.1517/14712598.5.4.477
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166. doi:10.1016/j.canlet.2014.03.013
   PubMed Web of Science ®Google Scholar
• Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013;19(40):7126–7140. doi:10.2174/13816128113199990493
   PubMed Web of Science ®Google Scholar
• Mazurek M, Litak J, Kamieniak P, et al. Metformin as potential therapy for high-grade glioma. Cancers (Basel). 2020;12(1).
   PubMedGoogle Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-1
   PubMed Web of Science ®Google Scholar
• Tomita T. Interstitial chemotherapy for brain tumors: review. J Neurooncol. 1991;10(1):57–74. doi:10.1007/BF00151247
   PubMed Web of Science ®Google Scholar
• Xu X, Chen X, Xu X, et al. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells. J Control Release. 2006;114(3):307–316.
   PubMed Web of Science ®Google Scholar
• Xie J, Macewan MR, Willerth SM, et al. Conductive core-sheath nanofibers and their potential application in neural tissue engineering. Adv Funct Mater. 2009;19(14):2312–2318. doi:10.1002/adfm.200801904
   PubMed Web of Science ®Google Scholar
• Yu M, Yao Q, Zhang Y, et al. Core/shell PLGA microspheres with controllable in vivo release profile via rational core phase design. Artif Cells Nanomed Biotechnol. 2018;1–10.
   Google Scholar
• Zhao M, Danhier F, Bastiancich C, et al. Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival. Int J Pharm. 2018;548(1):522–529. doi:10.1016/j.ijpharm.2018.07.033
   PubMedGoogle Scholar
• Lee JS, An TK, Chae GS, et al. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm. 2005;59(1):169–175. doi:10.1016/j.ejpb.2004.06.006
   PubMed Web of Science ®Google Scholar
• Seong H, An TK, Khang G, Choi SU, Lee CO, Lee HB. BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm. 2003;251(1–2):1–12. doi:10.1016/S0378-5173(02)00543-4
   PubMedGoogle Scholar
• Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol. 1997;39(5):383–389. doi:10.1007/s002800050588
   PubMed Web of Science ®Google Scholar
• Tyler B, Wadsworth S, Recinos V, et al. Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol. 2011;13(7):700–709. doi:10.1093/neuonc/nor050
   PubMedGoogle Scholar
• Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer. 1995;62(5):605–609. doi:10.1002/ijc.2910620519
   PubMed Web of Science ®Google Scholar
• Palakurthi S. Challenges in SN38 drug delivery: current success and future directions. Expert Opin Drug Deliv. 2015;12(12):1911–1921. doi:10.1517/17425247.2015.1070142
   PubMed Web of Science ®Google Scholar
• Zhang R, Saito R, Mano Y, et al. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models. Drug Deliv. 2016;23(8):2780–2786. doi:10.3109/10717544.2015.1081994
   PubMed Web of Science ®Google Scholar
• Manaspon C, Nasongkla N, Chaimongkolnukul K, et al. Injectable SN-38-loaded polymeric depots for cancer chemotherapy of glioblastoma multiforme. Pharm Res. 2016;33(12):2891–2903. doi:10.1007/s11095-016-2011-4
   PubMed Web of Science ®Google Scholar
• Zhu X, Ni S, Xia T, et al. Anti-neoplastic cytotoxicity of SN-38-loaded PCL/gelatin electrospun composite nanofiber scaffolds against human glioblastoma cells in vitro. J Pharm Sci. 2015;104(12):4345–4354. doi:10.1002/jps.24684
   PubMed Web of Science ®Google Scholar
• Affronti ML, Heery CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115(15):3501–3511. doi:10.1002/cncr.24398
   PubMedGoogle Scholar
• Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani M. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol. 2017;1–16.
   Google Scholar
• Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani M. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol. 2018;46(6):1095–1110. doi:10.1080/21691401.2017.1376675
   PubMed Web of Science ®Google Scholar
• Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer. 2003;97(9 Suppl):2359–2362. doi:10.1002/cncr.11305
   PubMedGoogle Scholar
• Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol. 2011;731:421–434.
   PubMedGoogle Scholar
• Haar CP, Hebbar P, Wallace GCT, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37(6):1192–1200. doi:10.1007/s11064-011-0701-1
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–1047. doi:10.1172/JCI9872
   PubMed Web of Science ®Google Scholar
• Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol. 1997;40(3):266–272. doi:10.1007/s002800050657
   PubMedGoogle Scholar
• Chen X, Zhang M, Gan H, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9(1):2949. doi:10.1038/s41467-018-05373-4
   PubMedGoogle Scholar
• Reijneveld JC, Voest EE, Taphoorn MJB. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol. 2000;247(8):597–608. doi:10.1007/s004150070128
   PubMedGoogle Scholar
• Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med. 2013;369(16):1561–1563. doi:10.1056/NEJMcibr1309402
   PubMed Web of Science ®Google Scholar
• Ahir BK, Engelhard HH, Lakka SS. Tumor development and angiogenesis in adult brain tumor: glioblastoma. Mol Neurobiol. 2020;57(5):2461–2478. doi:10.1007/s12035-020-01892-8
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol. 2010;2010:689018. doi:10.1155/2010/689018
   PubMedGoogle Scholar
• Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002;99(1):1–6. doi:10.1002/ijc.10316
   PubMed Web of Science ®Google Scholar
• Adair JE, Johnston SK, Mrugala MM, et al. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest. 2014;124(9):4082–4092. doi:10.1172/JCI76739
   PubMed Web of Science ®Google Scholar
• Tseng YY, Yang TC, Wang YC, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. Int J Nanomedicine. 2017;12:1265–1276.
   PubMed Web of Science ®Google Scholar
• Wurth R, Pattarozzi A, Gatti M, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle. 2013;12(1):145–156. doi:10.4161/cc.23050
   PubMed Web of Science ®Google Scholar
• Lee JE, Lim JH, Hong YK, Yang SH. High-dose metformin plus temozolomide shows increased anti-tumor effects in glioblastoma in vitro and in vivo compared with monotherapy. Cancer Res Treat. 2018;50(4):1331–1342. doi:10.4143/crt.2017.466
   PubMedGoogle Scholar
• Adeberg S, Bernhardt D, Harrabi SB, et al. Metformin enhanced in vitro radiosensitivity associates with G2/M cell cycle arrest and elevated adenosine-5ʹ-monophosphate-activated protein kinase levels in glioblastoma. Radiol Oncol. 2017;51(4):431–437. doi:10.1515/raon-2017-0042
   PubMedGoogle Scholar
• Taghizadehghalehjoughi A, Hacimuftuoglu A, Cetin M, et al. Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies. Nanomedicine (Lond). 2018;13(13):1595–1606. doi:10.2217/nnm-2017-0386
   PubMedGoogle Scholar
• Orunoglu M, Kaffashi A, Pehlivan SB, et al. Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model. Mater Sci Eng C Mater Biol Appl. 2017;78:32–38. doi:10.1016/j.msec.2017.03.292
   PubMed Web of Science ®Google Scholar
• Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med. 2003;138(8):659–668. doi:10.7326/0003-4819-138-8-200304150-00014
   PubMedGoogle Scholar
• Sneed PK, Stauffer PR, Gutin PH, et al. Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors. Neurosurgery. 1991;28(2):206–215. doi:10.1227/00006123-199102000-00006
   PubMed Web of Science ®Google Scholar
• Gillette EL. Clinical use of thermal enhancement and therapeutic gain for hyperthermia combined with radiation or drugs. Cancer Res. 1984;44(10 Suppl):4836s–4841s.
   PubMedGoogle Scholar
• Holste KG, Orringer DA. Laser interstitial thermal therapy. Neurooncol Adv. 2020;2(1):vdz035. doi:10.1093/noajnl/vdz035
   PubMedGoogle Scholar
• Pinel S, Thomas N, Boura C, Barberi-Heyob M. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. Adv Drug Deliv Rev. 2019;138:344–357. doi:10.1016/j.addr.2018.10.013
   PubMed Web of Science ®Google Scholar
• Shirvalilou S, Khoei S, Esfahani AJ, et al. Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review. J Neurooncol. 2021;152(3):419–428. doi:10.1007/s11060-021-03729-3
   PubMedGoogle Scholar
• Salehi A, Kamath AA, Leuthardt EC, Kim AH. Management of intracranial metastatic disease with laser interstitial thermal therapy. Front Oncol. 2018;8:499. doi:10.3389/fonc.2018.00499
   PubMed Web of Science ®Google Scholar
• Hsu SPC, Dhawan U, Tseng YY, et al. Glioma-sensitive delivery of angiopep-2 conjugated iron gold alloy nanoparticles ensuring simultaneous tumor imaging and hyperthermia mediated cancer theranostics. Appl Mater Today. 2020;18:100510. doi:10.1016/j.apmt.2019.100510
   Web of Science ®Google Scholar
• Kamath AA, Friedman DD, Akbari SHA, et al. Glioblastoma treated with magnetic resonance imaging-guided laser interstitial thermal therapy: safety, efficacy, and outcomes. Neurosurgery. 2019;84(4):836–843. doi:10.1093/neuros/nyy375
   PubMed Web of Science ®Google Scholar
• Li S, Deng Q, Li X, et al. Bis-diketopyrrolopyrrole conjugated polymer nanoparticles as photothermic nanoagonist for specific and synergistic glioblastoma therapy. Biomaterials. 2019;216:119252. doi:10.1016/j.biomaterials.2019.119252
   PubMed Web of Science ®Google Scholar
• Ohtake M, Umemura M, Sato I, et al. Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment. Sci Rep. 2017;7:42783. doi:10.1038/srep42783
   PubMed Web of Science ®Google Scholar
• Borasi G, Nahum A, Paulides MM, et al. Fast and high temperature hyperthermia coupled with radiotherapy as a possible new treatment for glioblastoma. J Ther Ultrasound. 2016;4(1):32. doi:10.1186/s40349-016-0078-3
   PubMedGoogle Scholar
• Avecillas-Chasin JM, Atik A, Mohammadi AM, Barnett GH. Laser thermal therapy in the management of high-grade gliomas. Int J Hyperthermia. 2020;37(2):44–52. doi:10.1080/02656736.2020.1767807
   PubMed Web of Science ®Google Scholar
• Thomas JG, Rao G, Kew Y, Prabhu SS. Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma. Neurosurg Focus. 2016;41(4):E12. doi:10.3171/2016.7.FOCUS16234
   PubMed Web of Science ®Google Scholar
• Lennernas H, Regardh CG. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm Res. 1993;10(6):879–883. doi:10.1023/A:1018965328626
   PubMedGoogle Scholar
• Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res. 2009;26(1):235–243. doi:10.1007/s11095-008-9697-x
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673–692. doi:10.2217/nnm.16.5
   PubMed Web of Science ®Google Scholar
• Liao WY, Li HJ, Chang MY, Tang AC, Hoffman AS, Hsieh PC. Comprehensive characterizations of nanoparticle biodistribution following systemic injection in mice. Nanoscale. 2013;5(22):11079–11086. doi:10.1039/c3nr03954d
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Junnuthula VR, Gowd GS, et al. Theranostic 3-dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. Sci Rep. 2017;7(1):43271. doi:10.1038/srep43271
   PubMedGoogle Scholar
• Sun L, Joh DY, Al-Zaki A, et al. Theranostic application of mixed gold and superparamagnetic iron oxide nanoparticle micelles in glioblastoma multiforme. J Biomed Nanotechnol. 2016;12(2):347–356. doi:10.1166/jbn.2016.2173
   PubMedGoogle Scholar
• Yao J, Hsu CH, Li Z, et al. Magnetic resonance nano-theranostics for glioblastoma multiforme. Curr Pharm Des. 2015;21(36):5256–5266. doi:10.2174/1381612821666150923103307
   PubMedGoogle Scholar
• Sonvico F, Clementino A, Buttini F, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics. 2018;10(1):34. doi:10.3390/pharmaceutics10010034
   PubMed Web of Science ®Google Scholar
• Cena V, Jativa P. Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases. Nanomedicine (Lond). 2018;13(13):1513–1516. doi:10.2217/nnm-2018-0139
   PubMedGoogle Scholar
• Saucier-Sawyer JK, Deng Y, Seo YE, et al. Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. J Drug Target. 2015;23(7–8):736–749. doi:10.3109/1061186X.2015.1065833
   PubMed Web of Science ®Google Scholar
• Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A. 2013;110(21):8662–8667. doi:10.1073/pnas.1307152110
   PubMed Web of Science ®Google Scholar
• Ou H, Cheng T, Zhang Y, et al. Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells. Acta Biomater. 2018;65:339–348. doi:10.1016/j.actbio.2017.10.034
   PubMed Web of Science ®Google Scholar
• Chen YC, Hsieh WY, Lee WF, Zeng DT. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J Biomater Appl. 2013;27(7):909–922. doi:10.1177/0885328211429495
   PubMed Web of Science ®Google Scholar
• Yang HW, Hua MY, Liu HL, et al. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials. 2011;32(27):6523–6532. doi:10.1016/j.biomaterials.2011.05.047
   PubMed Web of Science ®Google Scholar
• Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284–304. doi:10.1016/j.addr.2009.11.002
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhang M, Zeng F, Jin H, Xu Q, Huang Y. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces. 2016;8(47):32159–32169. doi:10.1021/acsami.6b10175
   PubMed Web of Science ®Google Scholar
• Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2006;78(1):7–14. doi:10.1007/s11060-005-9059-z
   PubMed Web of Science ®Google Scholar
• Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol. 2012;5(2):173–186. doi:10.1586/ecp.12.1
   PubMed Web of Science ®Google Scholar
• Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487–496. doi:10.1016/j.biomaterials.2007.08.050
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu F, Cole AJ, et al. Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J. 2009;11(4):693–699. doi:10.1208/s12248-009-9151-y
   PubMedGoogle Scholar
• Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release. 2007;122(3):315–323. doi:10.1016/j.jconrel.2007.05.030
   PubMed Web of Science ®Google Scholar
• Liu H-L, Hua M-Y, Chen P-Y, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255(2):415–425. doi:10.1148/radiol.10090699
   PubMed Web of Science ®Google Scholar
• Yang FY, Lin YS, Kang KH, Chao TK. Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release. 2011;150(1):111–116. doi:10.1016/j.jconrel.2010.10.038
   PubMed Web of Science ®Google Scholar
• Yang FY, Teng MC, Lu M, et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int J Nanomedicine. 2012;7:965–974. doi:10.2147/IJN.S29229
   PubMed Web of Science ®Google Scholar
• Yang FY, Wang HE, Lin GL, et al. Micro-SPECT/CT-based pharmacokinetic analysis of 99mTc-diethylenetriaminepentaacetic acid in rats with blood-brain barrier disruption induced by focused ultrasound. J Nucl Med. 2011;52(3):478–484. doi:10.2967/jnumed.110.083071
   PubMedGoogle Scholar
• Brighi C, Reid L, White AL, et al. MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neurooncol Adv. 2020;2(1):vdaa030. doi:10.1093/noajnl/vdaa030
   PubMedGoogle Scholar
• Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, Rutka JT. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus. 2012;32(1):E3. doi:10.3171/2011.10.FOCUS11252
   PubMed Web of Science ®Google Scholar
• Ohta S, Kikuchi E, Ishijima A, Azuma T, Sakuma I, Ito T. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening. Sci Rep. 2020;10(1):18220. doi:10.1038/s41598-020-75253-9
   PubMed Web of Science ®Google Scholar
• Houston ZH, Bunt J, Chen KS, et al. Understanding the uptake of nanomedicines at different stages of brain cancer using a modular nanocarrier platform and precision bispecific antibodies. ACS Cent Sci. 2020;6(5):727–738. doi:10.1021/acscentsci.9b01299
   PubMedGoogle Scholar
• Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010;107(34):15205–15210. doi:10.1073/pnas.1003388107
   PubMed Web of Science ®Google Scholar
• Li Y, Wu M, Zhang N, et al. Mechanisms of enhanced antiglioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound. J Cell Mol Med. 2018;22(9):4171–4182. doi:10.1111/jcmm.13695
   PubMed Web of Science ®Google Scholar
• Hua MY, Liu HL, Yang HW, et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials. 2011;32(2):516–527. doi:10.1016/j.biomaterials.2010.09.065
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109(5):759–767. doi:10.1002/ijc.20048
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Khalansky AS, Gelperina S, et al. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One. 2011;6(5):e19121. doi:10.1371/journal.pone.0019121
   PubMed Web of Science ®Google Scholar
• Roullin VG, Deverre JR, Lemaire L, et al. Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm. 2002;53(3):293–299. doi:10.1016/S0939-6411(02)00011-5
   PubMedGoogle Scholar
• Menei P, Boisdron-Celle M, Croue A, Guy G, Benoit JP. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 1996;39(1):117–123; discussion 123–114. doi:10.1097/00006123-199607000-00023
   PubMed Web of Science ®Google Scholar
• Dalbasti T, Oktar N, Cagli S, Ozdamar N. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. J Neurooncol. 2002;56(2):167–174. doi:10.1023/A:1014583820223
   PubMedGoogle Scholar
• Ward SM, Skinner M, Saha B, Emrick T. Polymer-temozolomide conjugates as therapeutics for treating glioblastoma. Mol Pharm. 2018;15(11):5263–5276. doi:10.1021/acs.molpharmaceut.8b00766
   PubMedGoogle Scholar
• Turek A, Stoklosa K, Borecka A, et al. Designing biodegradable wafers based on poly(L-lactide-co-glycolide) and poly(glycolide-co-epsilon-caprolactone) for the prolonged and local release of idarubicin for the therapy of glioblastoma multiforme. Pharm Res. 2020;37(5):90. doi:10.1007/s11095-020-02810-2
   PubMed Web of Science ®Google Scholar
• Nance E, Zhang C, Shih TY, Xu Q, Schuster BS, Hanes J. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano. 2014;8(10):10655–10664. doi:10.1021/nn504210g
   PubMed Web of Science ®Google Scholar
• Lee J, Cho HR, Cha GD, et al. Flexible, sticky, and biodegradable wireless device for drug delivery to brain tumors. Nat Commun. 2019;10(1):5205. doi:10.1038/s41467-019-13198-y
   PubMedGoogle Scholar
• Tzeng SY, Green JJ. Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. Adv Healthc Mater. 2013;2(3):468–480. doi:10.1002/adhm.201200257
   PubMed Web of Science ®Google Scholar
• Bikhezar F, de Kruijff RM, van der Meer A, et al. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. J Neurooncol. 2020;146(2):239–246. doi:10.1007/s11060-019-03365-y
   PubMed Web of Science ®Google Scholar
• Van Woensel M, Mathivet T, Wauthoz N, et al. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by galectin-1 intranasal knock-down strategy. Sci Rep. 2017;7(1):1217. doi:10.1038/s41598-017-01279-1
   PubMedGoogle Scholar
• Van Woensel M, Wauthoz N, Rosiere R, et al. Development of siRNA-loaded chitosan nanoparticles targeting galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release. 2016;227:71–81. doi:10.1016/j.jconrel.2016.02.032
   PubMed Web of Science ®Google Scholar